Dr Reddy's and Ingenus Pharma Ink Pact For Cancer Treatment Injection

Dr Reddy's Laboratories Ltd, an India-based multinational pharmaceutical company, has entered into a licensing agreement with US-based Ingenus Pharmaceuticals, LLC to market cyclophosphamide injection, which is used to treat cancer. The organization's wholly-owned subsidiary Dr Reddy's Laboratories Inc. and Ingenus Pharmaceuticals, LLC have entered into a license pact, Dr Reddy's Laboratories Ltd (DRL) said in an administrative filing.

Dr Reddy's Research facilities Inc (Dr Reddy's USA) has authorized from Ingenus, the select privileges to market Cyclophosphamide injection of strengths 500 mg/2.5mL; 1g/5mL; 2g/10mL in the US, it added. According to the filing, Dr. Reddy's USA will commercialize the cyclophosphamide injection for the US market under the in-licensing agreement. The company will pay Ingenus 50% of the calculated profit share and will not pay any other consideration.

According to the IQVIA, the said Ingenus product sold for $51.8 million in the last twelve months ended March 2024. According to the company, the parties will enter into a commercial supply agreement under which Ingenus will supply the product to Dr. Reddy's USA.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical firm located in Hyderabad. Dr. Reddy produces and markets a wide range of pharmaceuticals in India and overseas. The organization produces more than 190 meds, 60 dynamic drug fixings (APIs) for drug fabricate, diagnostic kits, critical care, and biotechnology.